Regeneron and Sanofi announce positive top line results from Phase III studies with sarilumab

Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase III study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Drug development Rheumatology Patient care DMARD HAQ-DI human IL-6 receptor antibody Latest News rheumatoid arthritis sarilumab TNF-IR Source Type: news